18 December 2020
The NASDAQ Biotechnology Index was launched in 1993 and is designed to track the performance of a set of securities listed on the
About
Syndax's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Syndax's expectations regarding the completion, timing and size of the proposed public offering. Words such as "may," "will," "expect," "plan," "anticipate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Syndax will be able to complete the proposed public offering on the anticipated terms, or at all. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the
2021 in Focus: Pharm Exec’s Annual Industry Outlook
15 January 2021
Research Eye stem cell transplant to treat blindness bolsters retinal function in monkeys
15 January 2021
Harnessing the power of a digital assistant to accelerate patient access
14 January 2021
A COVID-19 treatment candidate that fuses tiny antibodies from llamas and alpacas shows promise
14 January 2021